Combining a potent CD45-targeting ADC with shielded HSCs generated a large therapeutic window, which solved the problem by enabling continued post-transplantation therapy and radical, but well tolerated, selective tumour eradication. The gene discussed is PTPRC; the disease is neoplasm.